Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Myelodysplastic Syndromes or Acute Myeloid Leukemia undergoing allogeneic hematopoietic stem cell transplantation with either peripheral blood or bone marrow as the source of hematopoietic stem cells~At the time of allogeneic HSCT:~* No prior allogeneic HSCT; and~* No more than 1 antigen mismatch at Human Leukocyte Antigen (HLA)-A, -B, -C, -DRB1 or -DQB1 locus for either related or unrelated donor; and~* Bone marrow blast \< 20% if MDS or ≤ 10% if AML; and~* Peripheral blood blast ≤ 5%~Be able to start study drug between 42 to 84 days following allogeneic HSCT~Post transplant bone marrow blast count ≤ 5% confirmed within 21 days prior to starting study therapy~Adequate engraftment within 14 days prior to starting study therapy:~* Absolute Neutrophil count (ANC) ≥ 1.0 x 10\^9/L without daily use of myeloid growth factor; and~* Platelet count 75 x 10\^9/L without platelet transfusion within one week.~Adequate organ function:~* Serum aspartate transaminase (AST) and alanine transaminase (ALT) \< 3 x upper limit of normal (ULN)~* Serum bilirubin \< 2 x ULN~* Serum creatinine \< 2 x ULN~Adequate coagulation (Prothrombin time \[PT\] ≤ 15 seconds, Partial thromboplastin time (PTT) ≤ 40 seconds, and/or International normalized ratio \[INR\] ≤ 1.5)~Have a negative serum pregnancy test (sensitivity of at least 25 mIU/mL at screening).~Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~Must agree to follow protocol-specified pregnancy precautions~Exclusion Criteria:~* Use of any of the following after transplantation and prior to starting oral azacitidine:~  * Chemotherapeutic agents for chemotherapy~ * Investigational agents/therapies~ * Azacitidine, decitabine or other demethylating agents~ * Lenalidomide, thalidomide and pomalidomide~Active Graft-versus-host disease (GVHD) grade II or higher~Any evidence of gastrointestinal (GI) GVHD~Concurrent use of corticosteroids equivalent of prednisone at a dose \> 0.5 mg/kg~Known active viral infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV)~Active uncontrolled systemic fungal, bacterial or viral infection~Presence of malignancies, other than MDS or AML, within the previous 12 months~Significant active cardiac disease within the previous 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CC-486 (Type: EXPERIMENTAL): Dose of 150 mg, 200 mg, or 300 mg once daily (QD) for the first 7, 10, or 14 days of each 28-day cycle, starting 42-84 days after transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).